InforSense and Tripos Announce Alliance to Improve Drug Discovery Decision-Making
News Dec 13, 2005
Tripos, Inc. and InforSense have announced an alliance to integrate Tripos' discovery informatics portfolio with the award-winning InforSense KDE workflow-based integrative analytics platform.
Through the alliance, Tripos joins InforSense's Open Workflow Partner Network (OWPN) and InforSense joins Tripos' Alliance Program as a Software Partner.
The two companies will also integrate Tripos' AUSPYX, SYBYL and UNITY technologies with both InforSense KDE and its 'in Oracle' enterprise analytics system, InforSense IOE.
This integration enables customers such as Bayer Healthcare who are using technology from both companies, to access and integrate Tripos' discovery informatics technologies within InforSense KDE.
"We are excited to work with InforSense to benefit our joint customers," said Bryan Koontz, senior vice president and general manager of Discovery Informatics at Tripos.
"The integrated Tripos-InforSense solution offers a powerful and flexible informatics platform for rapid application development and deployment, and takes advantage of our standardization on web services and related Service-Oriented Informatics (SOI) technologies."
"The technical alliance between Tripos and InforSense is a successful example of this strategy, providing mutual customers with even more options for deploying innovative science and discovery software in an open workflow environment."
"Our customers require seamless interoperability between their choice of data resources, analytic tools and services," commented Joseph F. Donahue, Chief Business Officer of InforSense.
"By combining the workflow technology of InforSense KDE with Tripos' innovative discovery informatics portfolio, we can provide our joint customers with a flexible and easy to use environment for their chemistry research that is able to integrate data and computing resources across the entire R&D organization."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE